Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 312 entries
Sorted by: Best Match Show Resources per page
Editorial (Thematic Issue: Polypharmacology in Drug Discovery).

Current pharmaceutical design

Scotti L, Scotti MT.
PMID: 27291593
Curr Pharm Des. 2016;22(21):3071-2.

No abstract available.

Cite
Scotti L, Scotti MT. Editorial (Thematic Issue: Polypharmacology in Drug Discovery). Curr Pharm Des. 2016;22(21):3071-2
Scotti, L., & Scotti, M. T. (2016). Editorial (Thematic Issue: Polypharmacology in Drug Discovery). Current pharmaceutical design, 22(21), 3071-2.
Scotti, Luciana, and Scotti, Marcus T. "Editorial (Thematic Issue: Polypharmacology in Drug Discovery)." Current pharmaceutical design vol. 22,21 (2016): 3071-2.
Scotti L, Scotti MT. Editorial (Thematic Issue: Polypharmacology in Drug Discovery). Curr Pharm Des. 2016;22(21):3071-2. PMID: 27291593.
Copy Download .nbib Format: NLM
Editorial (Thematic Issue: Perspectives and Challenges in Rational Exploitation of Phytochemicals in Cure, Control and Management of Diseases).

Current pharmaceutical design

Raut JS, Deol PK, Kaur IP.
PMID: 27552902
Curr Pharm Des. 2016;22(27):4095-7. doi: 10.2174/1381612822999160624100330.

No abstract available.

Cite
Raut JS, Deol PK, Kaur IP. Editorial (Thematic Issue: Perspectives and Challenges in Rational Exploitation of Phytochemicals in Cure, Control and Management of Diseases). Curr Pharm Des. 2016;22(27):4095-7doi: 10.2174/1381612822999160624100330.
Raut, J. S., Deol, P. K., & Kaur, I. P. (2016). Editorial (Thematic Issue: Perspectives and Challenges in Rational Exploitation of Phytochemicals in Cure, Control and Management of Diseases). Current pharmaceutical design, 22(27), 4095-7. https://doi.org/10.2174/1381612822999160624100330
Raut, Jayant Shankar, et al. "Editorial (Thematic Issue: Perspectives and Challenges in Rational Exploitation of Phytochemicals in Cure, Control and Management of Diseases)." Current pharmaceutical design vol. 22,27 (2016): 4095-7. doi: https://doi.org/10.2174/1381612822999160624100330
Raut JS, Deol PK, Kaur IP. Editorial (Thematic Issue: Perspectives and Challenges in Rational Exploitation of Phytochemicals in Cure, Control and Management of Diseases). Curr Pharm Des. 2016;22(27):4095-7. doi: 10.2174/1381612822999160624100330. PMID: 27552902.
Copy Download .nbib Format: NLM
Psychosocial Risk Factors Related to Ischemic Heart Disease in Women.

Current pharmaceutical design

Varghese T, Hayek SS, Shekiladze N, Schultz WM, Wenger NK.
PMID: 27194439
Curr Pharm Des. 2016;22(25):3853-70. doi: 10.2174/1381612822666160519113605.

BACKGROUND: Psychosocial risk factors such as stress and psychiatric disorders are known to have negative impacts on health outcomes, but their effects on ischemic heart disease, particularly in women, remain to be fully understood despite contributing to one-third of...

Cite
Varghese T, Hayek SS, Shekiladze N, et al. Psychosocial Risk Factors Related to Ischemic Heart Disease in Women. Curr Pharm Des. 2016;22(25):3853-70doi: 10.2174/1381612822666160519113605.
Varghese, T., Hayek, S. S., Shekiladze, N., Schultz, W. M., & Wenger, N. K. (2016). Psychosocial Risk Factors Related to Ischemic Heart Disease in Women. Current pharmaceutical design, 22(25), 3853-70. https://doi.org/10.2174/1381612822666160519113605
Varghese, Tina, et al. "Psychosocial Risk Factors Related to Ischemic Heart Disease in Women." Current pharmaceutical design vol. 22,25 (2016): 3853-70. doi: https://doi.org/10.2174/1381612822666160519113605
Varghese T, Hayek SS, Shekiladze N, Schultz WM, Wenger NK. Psychosocial Risk Factors Related to Ischemic Heart Disease in Women. Curr Pharm Des. 2016;22(25):3853-70. doi: 10.2174/1381612822666160519113605. PMID: 27194439.
Copy Download .nbib Format: NLM
Beneficial effects of the Mediterranean diet on metabolic syndrome.

Current pharmaceutical design

Grosso G, Mistretta A, Marventano S, Purrello A, Vitaglione P, Calabrese G, Drago F, Galvano F.
PMID: 24320030
Curr Pharm Des. 2014;20(31):5039-44. doi: 10.2174/1381612819666131206112144.

The metabolic syndrome (MetS) represents a cluster of medical disorders, such as hyperglycemia, dyslipidemia, hypertension, and abdominal obesity that, when occurring together, increase the risk of developing cardiovascular disease. The role of food and nutrients in the aetiology of...

Cite
Grosso G, Mistretta A, Marventano S, et al. Beneficial effects of the Mediterranean diet on metabolic syndrome. Curr Pharm Des. 2014;20(31):5039-44doi: 10.2174/1381612819666131206112144.
Grosso, G., Mistretta, A., Marventano, S., Purrello, A., Vitaglione, P., Calabrese, G., Drago, F., & Galvano, F. (2014). Beneficial effects of the Mediterranean diet on metabolic syndrome. Current pharmaceutical design, 20(31), 5039-44. https://doi.org/10.2174/1381612819666131206112144
Grosso, Giuseppe, et al. "Beneficial effects of the Mediterranean diet on metabolic syndrome." Current pharmaceutical design vol. 20,31 (2014): 5039-44. doi: https://doi.org/10.2174/1381612819666131206112144
Grosso G, Mistretta A, Marventano S, Purrello A, Vitaglione P, Calabrese G, Drago F, Galvano F. Beneficial effects of the Mediterranean diet on metabolic syndrome. Curr Pharm Des. 2014;20(31):5039-44. doi: 10.2174/1381612819666131206112144. PMID: 24320030.
Copy Download .nbib Format: NLM
Statins and inflammation in cardiovascular disease.

Current pharmaceutical design

Vogiatzi G, Oikonomou E, Siasos G, Tsalamandris S, Briasoulis A, Androulakis E, Latsios G, Papaioannou S, Tsioufis K, Tousoulis D.
PMID: 28990524
Curr Pharm Des. 2017 Oct 09; doi: 10.2174/1381612823666171009141201. Epub 2017 Oct 09.

BACKGROUND: Chronic inflammation and immune system activation underlie a variety of seemingly unrelated cardiac conditions including not only atherosclerosis and the subsequent coronary artery disease but also peripheral artery disease, hypertension with target organ damage and heart failure. The...

Cite
Vogiatzi G, Oikonomou E, Siasos G, et al. Statins and inflammation in cardiovascular disease. Curr Pharm Des. 2017;doi: 10.2174/1381612823666171009141201.
Vogiatzi, G., Oikonomou, E., Siasos, G., Tsalamandris, S., Briasoulis, A., Androulakis, E., Latsios, G., Papaioannou, S., Tsioufis, K., & Tousoulis, D. (2017). Statins and inflammation in cardiovascular disease. Current pharmaceutical design, . https://doi.org/10.2174/1381612823666171009141201
Vogiatzi, Georgia, et al. "Statins and inflammation in cardiovascular disease." Current pharmaceutical design vol. (2017). doi: https://doi.org/10.2174/1381612823666171009141201
Vogiatzi G, Oikonomou E, Siasos G, Tsalamandris S, Briasoulis A, Androulakis E, Latsios G, Papaioannou S, Tsioufis K, Tousoulis D. Statins and inflammation in cardiovascular disease. Curr Pharm Des. 2017 Oct 09; doi: 10.2174/1381612823666171009141201. Epub 2017 Oct 09. PMID: 28990524.
Copy Download .nbib Format: NLM
Tailored Multi-Target Agents. Applications and Design Considerations.

Current pharmaceutical design

Talevi A.
PMID: 26951108
Curr Pharm Des. 2016;22(21):3164-70. doi: 10.2174/1381612822666160308141203.

BACKGROUND: In contrast to the one target-one drug paradigm, multi-target agents seem as a promising alternative to manage complex disorders and health conditions linked to drug resistance issues. In fact, many longstanding drugs are in fact unintended multi-functional therapeutics...

Cite
Talevi A. Tailored Multi-Target Agents. Applications and Design Considerations. Curr Pharm Des. 2016;22(21):3164-70doi: 10.2174/1381612822666160308141203.
Talevi, A. (2016). Tailored Multi-Target Agents. Applications and Design Considerations. Current pharmaceutical design, 22(21), 3164-70. https://doi.org/10.2174/1381612822666160308141203
Talevi, Alan. "Tailored Multi-Target Agents. Applications and Design Considerations." Current pharmaceutical design vol. 22,21 (2016): 3164-70. doi: https://doi.org/10.2174/1381612822666160308141203
Talevi A. Tailored Multi-Target Agents. Applications and Design Considerations. Curr Pharm Des. 2016;22(21):3164-70. doi: 10.2174/1381612822666160308141203. PMID: 26951108.
Copy Download .nbib Format: NLM
1,N6-ethenoadenine and other Fluorescent Nucleobase Analogues as Substrates for Purine-Nucleoside Phosphorylases: Spectroscopic and Kinetic Studies.

Current pharmaceutical design

Wierzchowski J, Stachelska-Wierzchowska A, Wielgus-Kutrowska B, Bzowska A.
PMID: 29022509
Curr Pharm Des. 2017 Oct 11; doi: 10.2174/1381612823666171011103551. Epub 2017 Oct 11.

BACKGROUND: Purine-nucleoside phosphorylase (PNP) is known as a tool for the synthesis of various nucleosides and nucleoside analogues. Mechanism, properties, molecular diversity and inhibitors of PNP, particularly these of pharmacological significance, are briefly characterized.METHODS: UV and fluorescence spectroscopy was...

Cite
Wierzchowski J, Stachelska-Wierzchowska A, Wielgus-Kutrowska B, et al. 1,N6-ethenoadenine and other Fluorescent Nucleobase Analogues as Substrates for Purine-Nucleoside Phosphorylases: Spectroscopic and Kinetic Studies. Curr Pharm Des. 2017;doi: 10.2174/1381612823666171011103551.
Wierzchowski, J., Stachelska-Wierzchowska, A., Wielgus-Kutrowska, B., & Bzowska, A. (2017). 1,N6-ethenoadenine and other Fluorescent Nucleobase Analogues as Substrates for Purine-Nucleoside Phosphorylases: Spectroscopic and Kinetic Studies. Current pharmaceutical design, . https://doi.org/10.2174/1381612823666171011103551
Wierzchowski, Jacek, et al. "1,N6-ethenoadenine and other Fluorescent Nucleobase Analogues as Substrates for Purine-Nucleoside Phosphorylases: Spectroscopic and Kinetic Studies." Current pharmaceutical design vol. (2017). doi: https://doi.org/10.2174/1381612823666171011103551
Wierzchowski J, Stachelska-Wierzchowska A, Wielgus-Kutrowska B, Bzowska A. 1,N6-ethenoadenine and other Fluorescent Nucleobase Analogues as Substrates for Purine-Nucleoside Phosphorylases: Spectroscopic and Kinetic Studies. Curr Pharm Des. 2017 Oct 11; doi: 10.2174/1381612823666171011103551. Epub 2017 Oct 11. PMID: 29022509.
Copy Download .nbib Format: NLM
Neonatal Formulations: The Need for a Tailored, Knowledge Driven Approach.

Current pharmaceutical design

Allegaert K, Cosaert K, van den Anker JN.
PMID: 26323412
Curr Pharm Des. 2015;21(39):5674-9. doi: 10.2174/1381612821666150901110207.

To attain effective and safe pharmacotherapy in neonates, caregivers have to consider both the clinical characteristics of the newborn and the pharmacokinetic estimates of a given compound during prescription and administration. Overall, clearance in neonates is low when compared...

Cite
Allegaert K, Cosaert K, van den Anker JN. Neonatal Formulations: The Need for a Tailored, Knowledge Driven Approach. Curr Pharm Des. 2015;21(39):5674-9doi: 10.2174/1381612821666150901110207.
Allegaert, K., Cosaert, K., & van den Anker, J. N. (2015). Neonatal Formulations: The Need for a Tailored, Knowledge Driven Approach. Current pharmaceutical design, 21(39), 5674-9. https://doi.org/10.2174/1381612821666150901110207
Allegaert, Karel, et al. "Neonatal Formulations: The Need for a Tailored, Knowledge Driven Approach." Current pharmaceutical design vol. 21,39 (2015): 5674-9. doi: https://doi.org/10.2174/1381612821666150901110207
Allegaert K, Cosaert K, van den Anker JN. Neonatal Formulations: The Need for a Tailored, Knowledge Driven Approach. Curr Pharm Des. 2015;21(39):5674-9. doi: 10.2174/1381612821666150901110207. PMID: 26323412.
Copy Download .nbib Format: NLM
Statins in Stable Angina Pectoris.

Current pharmaceutical design

Ioannou A, Papageorgiou N, McVaughan V, Charakida M, Bertsias D, Zacharia F, Siasos G, Latsios G, Papaioannou S, Oikonomou E, Tousoulis D.
PMID: 28847306
Curr Pharm Des. 2017 Aug 28; doi: 10.2174/1381612823666170828132303. Epub 2017 Aug 28.

BACKGROUND: Stable angina is a debilitating and progressive disease caused by narrowing of the coronary arteries, which in turn affects cardiac perfusion. Statins have a well-established role, modifying symptoms and progression of the disease not only through lipid lowering,...

Cite
Ioannou A, Papageorgiou N, McVaughan V, et al. Statins in Stable Angina Pectoris. Curr Pharm Des. 2017;doi: 10.2174/1381612823666170828132303.
Ioannou, A., Papageorgiou, N., McVaughan, V., Charakida, M., Bertsias, D., Zacharia, F., Siasos, G., Latsios, G., Papaioannou, S., Oikonomou, E., & Tousoulis, D. (2017). Statins in Stable Angina Pectoris. Current pharmaceutical design, . https://doi.org/10.2174/1381612823666170828132303
Ioannou, Adam, et al. "Statins in Stable Angina Pectoris." Current pharmaceutical design vol. (2017). doi: https://doi.org/10.2174/1381612823666170828132303
Ioannou A, Papageorgiou N, McVaughan V, Charakida M, Bertsias D, Zacharia F, Siasos G, Latsios G, Papaioannou S, Oikonomou E, Tousoulis D. Statins in Stable Angina Pectoris. Curr Pharm Des. 2017 Aug 28; doi: 10.2174/1381612823666170828132303. Epub 2017 Aug 28. PMID: 28847306.
Copy Download .nbib Format: NLM
A Perspective on Rational Designs of a Hemagglutinin Based Universal Influenza Vaccine.

Current pharmaceutical design

Van TD, Tran N, Le L, Eisenhaber F.
PMID: 24308491
Curr Pharm Des. 2016 Apr 19; Epub 2016 Apr 19.

BACKGROUND: The influenza virus is one of the most critical threats to public health with major economic impact. Though annual influenza vaccination is currently the most effective prevention strategy against flu epidemics and pandemics, the mutational evolution of the...

Cite
Van TD, Tran N, Le L, et al. A Perspective on Rational Designs of a Hemagglutinin Based Universal Influenza Vaccine. Curr Pharm Des. 2016;
Van, T. D., Tran, N., Le, L., & Eisenhaber, F. (2016). A Perspective on Rational Designs of a Hemagglutinin Based Universal Influenza Vaccine. Current pharmaceutical design, .
Van, Thanh D, et al. "A Perspective on Rational Designs of a Hemagglutinin Based Universal Influenza Vaccine." Current pharmaceutical design vol. (2016).
Van TD, Tran N, Le L, Eisenhaber F. A Perspective on Rational Designs of a Hemagglutinin Based Universal Influenza Vaccine. Curr Pharm Des. 2016 Apr 19; Epub 2016 Apr 19. PMID: 24308491.
Copy Download .nbib Format: NLM
Stress echocardiography.

Current pharmaceutical design

Picano E, Pasanisi E, Venneri L, Agrusta M, Mottola G, Sicari R.
PMID: 16026284
Curr Pharm Des. 2005;11(17):2137-49. doi: 10.2174/1381612054367454.

Stress echocardiography is the combination of 2D echocardiography with a physical, pharmacological or electrical stress. The diagnostic end point for the detection of myocardial ischemia is the induction of a transient worsening in regional function during stress. Stress echocardiography...

Cite
Picano E, Pasanisi E, Venneri L, et al. Stress echocardiography. Curr Pharm Des. 2005;11(17):2137-49doi: 10.2174/1381612054367454.
Picano, E., Pasanisi, E., Venneri, L., Agrusta, M., Mottola, G., & Sicari, R. (2005). Stress echocardiography. Current pharmaceutical design, 11(17), 2137-49. https://doi.org/10.2174/1381612054367454
Picano, E, et al. "Stress echocardiography." Current pharmaceutical design vol. 11,17 (2005): 2137-49. doi: https://doi.org/10.2174/1381612054367454
Picano E, Pasanisi E, Venneri L, Agrusta M, Mottola G, Sicari R. Stress echocardiography. Curr Pharm Des. 2005;11(17):2137-49. doi: 10.2174/1381612054367454. PMID: 16026284.
Copy Download .nbib Format: NLM
Pathophysiology and therapeutics of cardiovascular health in metabolic syndrome.

Current pharmaceutical design

Zhang Y, Ren J.
PMID: 23323623
Curr Pharm Des. 2013 Jan 11; Epub 2013 Jan 11.

No abstract available.

Cite
Zhang Y, Ren J. Pathophysiology and therapeutics of cardiovascular health in metabolic syndrome. Curr Pharm Des. 2013;
Zhang, Y., & Ren, J. (2013). Pathophysiology and therapeutics of cardiovascular health in metabolic syndrome. Current pharmaceutical design, .
Zhang, Yingmei, and Ren, Jun. "Pathophysiology and therapeutics of cardiovascular health in metabolic syndrome." Current pharmaceutical design vol. (2013).
Zhang Y, Ren J. Pathophysiology and therapeutics of cardiovascular health in metabolic syndrome. Curr Pharm Des. 2013 Jan 11; Epub 2013 Jan 11. PMID: 23323623.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 312 entries